Table 1.

Effect of the ASP interruption during COVID-19 pandemic on antibiotic consumption in the 4 medical units included in the study.

Antibiotics	Parameter Evaluated	Effect Estimate	LCI	UCI	p Value
Carbapenems	Change in trend	1.69	−1.27	4.65	0.24
	Change in level	3.22	−8.98	15.41	0.58
Piperacillin/tazobactam	Change in trend	−0.45	−1.72	0.82	0.47
	Change in level	−1.52	−9.88	6.85	0.70
III/IV Generation Cephalosporins	Change in trend	1.12	−1.04	3.29	0.29
	Change in level	−3.72	−13.96	6.51	0.45
Aminopenicillins/BLI	Change in trend	3.25	−0.17	6.67	0.061
	Change in level	2.50	−14.54	19.54	0.76
Fluoroquinolones	Change in trend	0.99	0.13	1.86	0.027
	Change in level	−0.94	−5.2	3.28	0.64
Vancomycin	Change in trend	0.49	−0.68	1.68	0.38
	Change in level	−1.93	−7.29	3.43	0.46
Linezolid	Change in trend	0.43	−0.58	1.43	0.38
	Change in level	1.29	1.29	2.38	0.59
Macrolides	Change in trend	0.069	−0.24	0.38	0.64
	Change in level	−0.011	−0.29	0.27	0.94
All antibiotics	Change in trend	15.44	−3.75	34.6	0.11
	Change in level	−3.08	−67.29	61.12	0.92
Costs	Change in trend	180.3	−108.2	468.8	0.20
	Change in level	−95.5	−1535.8	1344.9	0.89